Long-term study of safety and Efficacy of roflumilast in Japanese patients with bronchial asthma (20 to 71 y) (APTA-2217-07)
Study identifier:APTA-2217-07
ClinicalTrials.gov identifier:NCT00246922
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A long-term study of APTA-2217 in adult patients with bronchial asthma
Medical condition
Bronchial Asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
Roflumilast
Sex
All
Actual Enrollment
150
Study type
Interventional
Age
20 Years - 71 Years
Date
Study Start Date: 01 Dec 2004
Primary Completion Date: 01 Jan 2007
Study Completion Date: 01 Oct 2007
Study design
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Sept 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
TANABE SEIYAKU Co., LTD.
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca AstraZeneca
AstraZeneca
